Upload your raw 23andMe, AncestryDNA, or whole genome sequencing file to map your likely GABA, glutamate, and neural-excitability drivers for free.
Feeling overstimulated does not always mean that you simply have “too much glutamate” or “not enough GABA.”
For many people, the deeper issue is how the brain converts glutamate into GABA, responds to excitatory signals, receives inhibitory signals, clears GABA after release, and removes excess glutamate from the signaling space.
That is why two people can both struggle to calm down while experiencing very different underlying patterns:
Mutant helps you move beyond generic “high glutamate” explanations and identify which part of the brain’s accelerator-and-brake system may be narrowing.
If you struggle with overstimulation, racing thoughts, sensory sensitivity, exaggerated startle, physical tension, panic-like activation, difficulty calming, nighttime shutdown, or unusual reactions to calming supplements, the next question is not simply:
How can I increase GABA?
The better question is:
Which part of my neural excitation-and-inhibition system is becoming unstable?
Mutant uses your raw DNA file to map GABA- and glutamate-related pathways across:
The current GABA, Glutamate & Neural Excitability hub models these pathways through genes including GAD1, GAD2, PDXK, GRIN2B, GABRA2, GABRA6, SLC6A1, ABAT, ALDH5A1, SLC1A2, SLC1A3, GRM3, and CACNA1C.
Mutant does not treat neural overactivation as one generic neurotransmitter imbalance.
It separates the GABA, Glutamate & Neural Excitability hub into five possible driver lanes:
Each lane points to a different interpretation.
One person may struggle to generate enough inhibitory GABA under demand. Another may receive an amplified excitatory signal. Another may produce GABA adequately but respond less reliably through GABA-A receptors. Another may terminate GABA signals too quickly or too slowly. Another may have less reserve for clearing glutamate between neurons.
These patterns can overlap, but they are not interchangeable.
That distinction matters because the strategy for limited GABA synthesis is not necessarily the same as the strategy for NMDA-receptor sensitivity, weak inhibitory receptor response, altered GABA degradation, or slow glutamate clearance.
Your brain may have less reserve for converting an activating neurotransmitter into an inhibitory one.
GABA is synthesized from glutamate through glutamate decarboxylase enzymes.
The two principal genes are:
The two enzymes have overlapping but distinct roles. GAD67 contributes substantially to baseline cellular GABA production, while GAD65 is closely associated with activity-dependent and synaptic GABA availability. Both depend on pyridoxal-5-phosphate, the active coenzyme form of vitamin B6.
Mutant also considers:
Vitamin B6 is required by glutamate decarboxylase, but a genetic tendency in this pathway does not establish that vitamin B6 intake or blood status is low.
The final system still depends on:
A person may have enough vitamin B6 while the functional bottleneck lies elsewhere.
A pathway involving vitamin B6 does not justify high-dose supplementation.
Excess supplemental vitamin B6 can cause peripheral neuropathy, and the risk is related to dose and duration. A genetic result should be interpreted alongside actual intake, laboratory context when appropriate, medication use, and symptoms rather than used as a reason to push progressively higher doses.
Some people also report activation, vivid dreams, insomnia, or other adverse effects from particular B6 forms or doses. Those reactions do not prove that GABA is high or low.
GABA demand is not constant.
The inhibitory system may appear adequate during quiet periods but lose reserve when the brain is exposed to:
A person may therefore feel calm much of the time but become disproportionately overwhelmed once demand crosses a threshold.
Stress hormones and autonomic activation can increase the amount of inhibitory control the brain needs.
If overstimulation includes adrenaline-like surges, heart-rate changes, shakiness, digestive urgency, or prolonged bodily recovery, read the Stress Axis & Autonomic Recovery DNA Analysis.
This is a GABA-production reserve problem, not proof of a fixed whole-brain GABA deficiency.
The conversion system may function adequately at baseline but become less reliable when neural demand rises.
A normal amount of glutamate may generate a stronger or more persistent excitatory response.
Glutamate is the brain’s principal excitatory neurotransmitter.
It communicates through several receptor families, including:
One important gene in the Mutant driver map is:
GRIN2B, which encodes the GluN2B subunit of the NMDA receptor
Mutant also considers related excitability pathways involving:
NMDA receptors are involved in synaptic communication, learning, memory, and neuronal development. GRIN2B contributes one of the receptor’s regulatory subunits, and functional changes in NMDA-receptor genes can produce either increased or decreased receptor activity depending on the specific variant.
Two people can have similar glutamate release but experience different levels of excitation.
The outcome depends on:
A person can therefore experience an amplified excitatory response without having globally excessive glutamate production.
NMDA receptors are essential for normal brain function.
They contribute to:
The goal is not to eliminate NMDA signaling.
Too little activity can also be disruptive. The relevant issue is whether receptor activity remains appropriately matched to context and inhibitory control.
Rare pathogenic variants in GRIN2B can cause serious neurodevelopmental disorders. That is a different category from the common regulatory variants used in a wellness-oriented driver model.
Mutant should not imply that a common SNP produces the same effect as a rare disease-causing mutation.
Common variants generally act as modest modifiers. Their value comes from convergence with:
A receptor-sensitivity pattern may remain relatively quiet until another factor increases glutamate release or lowers inhibitory control.
Possible amplifiers include:
The variant may not create the entire problem. It may make the system respond more strongly when another stressor is present.
Dopamine and norepinephrine can increase mental activation and attention.
If that activation becomes disorganized, overly intense, or difficult to terminate, glutamate-related excitability may be amplifying a catecholamine problem.
Read the Catecholamines & Executive Arousal DNA Analysis if overstimulation overlaps with distractibility, task-initiation difficulty, hyperfocus, reward seeking, caffeine dependence, or unstable stimulant response.
This is an excitatory receptor-response problem, not necessarily evidence that the brain is producing too much glutamate.
A normal signal may feel unusually loud because the receiving system is more reactive.
GABA may be produced and released, but the inhibitory message may not be received as reliably as expected.
GABA produces many of its rapid inhibitory effects through GABA-A receptors.
These receptors are chloride channels assembled from different combinations of protein subunits. Their subunit composition influences:
Important genes in this lane include:
GABA can act through synaptic receptors that produce faster, phasic inhibition and extrasynaptic receptors that contribute to more sustained, tonic inhibition. Receptor subunit composition helps determine these functional differences.
A neurotransmitter must be:
A person can have reasonable GABA synthesis while the receptor-level effect is less stable.
This is why increasing GABA production does not necessarily correct a receptor-signaling problem.
Phasic inhibition is produced by brief GABA release at a synapse. It helps interrupt and shape specific neural signals.
Tonic inhibition reflects a more continuous inhibitory influence created by GABA acting outside traditional synaptic release events.
A person may therefore have difficulty with:
This distinction may help explain why someone can calm briefly but remain vulnerable to immediate reactivation.
Some studies have linked GABA-receptor variation with stress response, alcohol-related traits, or emotional regulation, while other studies have failed to find strong or replicable associations with broad anxiety diagnoses.
That means a common receptor variant should not be interpreted as:
Mutant uses receptor variants only as one component of a converging driver pattern.
A substance may reduce awareness, slow reaction time, or cause sleepiness without restoring balanced inhibition.
Someone can feel:
The subjective feeling of sedation does not directly measure healthy GABA-A receptor function.
Alcohol interacts with GABAergic and other neurotransmitter systems, but short-term calming does not mean alcohol is correcting a genetic GABA problem.
Repeated alcohol exposure can alter receptor regulation, sleep, stress response, and withdrawal-related excitability. Genetic results involving GABA receptors should never be used to justify alcohol as a treatment strategy.
The ability to maintain nighttime inhibition depends partly on whether the circadian system is signaling the correct biological time for sleep.
Read the Circadian & Sleep-Wake DNA Analysis if poor calming is most severe at night or overlaps with delayed sleep, early waking, fragmented sleep, caffeine sensitivity, or an evening second wind.
This is an inhibitory receptor-response problem, not necessarily a shortage of GABA production.
The inhibitory signal may be present but translated less consistently into neural restraint.
GABA signals may be terminated, recycled, or metabolized at a rate that does not match the brain’s needs.
After GABA is released, it must be removed from the extracellular space and either recycled or metabolized.
Important genes in this lane include:
GAT1 participates in GABA reuptake and helps regulate extracellular GABA concentrations. ABAT converts GABA into succinic semialdehyde, and ALDH5A1 processes that intermediate within the mitochondrial GABA-shunt pathway.
GABA transporters help terminate signaling and prevent uncontrolled spillover.
If GABA is removed too quickly in a particular circuit, inhibitory signals may not persist long enough.
If GABA remains outside cells longer, inhibition may increase—but that is not automatically better. Excessive or poorly located inhibition can impair:
The goal is appropriate signal duration, not maximum extracellular GABA.
Reuptake does not determine whether GABA will be reused or broken down.
Once inside a neuron or glial cell, GABA can enter the GABA-shunt pathway. ABAT and ALDH5A1 connect neurotransmitter handling with mitochondrial metabolism.
That means transporter and degradation pathways must be interpreted together.
Two people with similar GABA uptake may differ in how much of that GABA is:
Pathogenic loss-of-function variants in SLC6A1, ABAT, or ALDH5A1 can cause serious neurological or developmental disorders.
Those rare variants are not equivalent to common SNPs included in a consumer genetic pattern analysis.
Mutant should clearly distinguish:
A wellness report should not suggest that a common allele causes a rare GABA-metabolism disorder.
Several medications affect GABA receptors, transport, or metabolism.
Their effects depend on:
A transporter or degradation variant cannot determine whether a medication will help, cause side effects, or what dose should be used.
GABA-related activation may feel like generalized neural intensity, while serotonin-related rumination often has persistent emotional or threat-focused content.
Read the Serotonin & Threat Regulation DNA Analysis if difficulty calming centers on repetitive worry, social-threat sensitivity, emotional replay, or an inability to mentally let go.
This is a signal-termination and metabolism problem, not simply a question of how much GABA is produced.
The inhibitory signal may be present but persist for too little or too much time—or be recycled less efficiently.
Glutamate may be released normally but remain in the signaling environment longer because clearance reserve is limited.
Neurons are not solely responsible for controlling glutamate.
Astrocytes—support cells surrounding synapses—play a major role in removing extracellular glutamate.
Important genes include:
EAAT1 and EAAT2 are highly expressed in astrocytes and are central to extracellular glutamate clearance. After uptake, astrocytes can convert glutamate into glutamine and return it to neurons, supporting the glutamate-glutamine recycling cycle.
Astrocytes help regulate the chemical environment surrounding neurons.
Their roles include:
Glutamate clearance is therefore not simply a receptor problem.
The brain must also remove the signal after it has served its purpose.
A person with somewhat reactive glutamate receptors may remain stable if extracellular glutamate is cleared quickly.
A person with somewhat slower glutamate clearance may remain stable if receptor sensitivity is low and GABA restraint is strong.
Symptoms may become louder when multiple vulnerabilities converge:
Mutant is designed to detect that convergence rather than overinterpreting one transporter result.
Glutamate transporters depend on cellular-energy and ion gradients.
Experimental research shows that oxidative conditions can reduce glutamate uptake in astrocytes, providing a plausible reason that a genetically modest clearance vulnerability may become more visible during illness, inflammation, or metabolic stress.
This does not mean oxidative stress is the universal explanation for symptoms. It means transporter reserve is context-dependent.
People often assume that glutamate-related activation should feel energetic or cognitively sharp.
But prolonged or poorly regulated excitation can feel like:
The person may feel both mentally overactive and cognitively impaired.
Inflammation, illness, nutrient handling, sleep disruption, and gut-derived immune signaling can influence neural tolerance.
If overstimulation tracks food reactions, intestinal inflammation, loose stools, abdominal discomfort, or immune flares, read the Gut, Barrier & Immune Reactivity DNA Analysis.
This is an excitatory signal-clearance problem, not necessarily excessive glutamate production.
The problem may be that the brain cannot remove and recycle glutamate as quickly as demand requires.
Most people trying to solve overstimulation encounter some version of:
Some approaches may help.
But they do not answer the central question:
Why is neural excitation becoming difficult to control?
The same intervention can affect different people in opposite ways.
For example:
When the standard approach plateaus, the next question is usually not:
How can I raise GABA or lower glutamate further?
It is:
Is the problem conversion, receptor response, signal termination, or clearance?
That is the gap Mutant is built to fill.
There is no single gene that establishes a person’s overall brain GABA or glutamate level.
A neural-excitability pattern can emerge through multiple routes:
This is why Mutant treats GABA, Glutamate & Neural Excitability as a parent pattern rather than a single-SNP result.
The goal is not to declare that GABA is low or glutamate is high.
The goal is to identify which control point may be contributing to the person’s actual symptoms and triggers.
GABA and glutamate regulation affects:
That creates substantial overlap with other Mutant hubs.
The GABA/Glutamate hub centers on:
The Serotonin hub centers more on:
A person may have a very active brain without repetitive threat content. Another may be physically calm while remaining trapped in worry loops.
Explore Serotonin & Threat Regulation
The Stress Axis hub centers on:
The GABA/Glutamate hub centers on:
Someone may have racing thoughts without a major heart-rate response. Another may experience strong physical adrenaline with relatively clear thinking.
Explore Stress Axis & Autonomic Recovery
The Catecholamine hub determines whether enough organized mental activation is available for focus, motivation, and effort.
The GABA/Glutamate hub influences whether that activation remains controlled.
A person can be both:
This can create a confusing pattern of procrastination, stimulant seeking, hyperfocus, anxiety, and crashes.
Explore Catecholamines & Executive Arousal
Circadian regulation determines when the brain expects wakefulness and sleep.
The GABA/Glutamate hub influences whether the nervous system can reduce activation during that sleep window.
A person may be at the correct biological bedtime but remain too neurologically activated to settle.
Explore Circadian & Sleep-Wake Regulation
Histamine is a wake-promoting and inflammatory mediator.
Histamine-related activation may include:
GABA/glutamate activation may feel more like generalized neural buzzing, sensory overload, tension, startle, or racing thoughts.
A product marketed as calming can act at several different points:
A negative reaction does not prove that GABA is already high.
Possible explanations include:
Mutant uses reaction history as contextual evidence, not as a direct neurotransmitter measurement.
Glutamate is a normal amino acid found in many foods and proteins.
The brain tightly regulates its own extracellular glutamate environment. Dietary glutamate does not simply move unchanged into the brain and determine synaptic glutamate levels.
However, people can still react to particular foods for other reasons, including:
A food reaction should therefore not automatically be labeled as brain glutamate toxicity.
The pattern, timing, reproducibility, dose, and other symptoms matter.
Mutant analyzes GABA, glutamate, and neural-excitability pathways across:
The goal is not to diagnose an anxiety disorder, epilepsy, autism, ADHD, panic disorder, sensory-processing disorder, or another neurological or psychiatric condition.
The goal is to organize genetic vulnerability patterns that may help explain:
Mutant is currently offering free genetic pattern scans as part of the platform’s early product buildout.
The goal is simple:
We are being upfront about that.
The free scan is the starting point.
The long-term product is a contextual AI companion designed to help users understand what their patterns may mean over time.
Your raw DNA file is not the product.
The interpretation layer is the product we are building.
Mutant supports two levels of DNA input.
Consumer DNA file analysis uses microarray data from 23andMe or AncestryDNA.
This can provide a useful first-pass map of common GABA, glutamate, and neural-excitability patterns.
A consumer DNA file may help answer questions such as:
Consumer microarrays do not cover every relevant variant. A missing result does not prove that a pathway is normal.
Learn more about 23andMe raw data analysis
Learn more about AncestryDNA raw data analysis
Whole genome sequencing provides broader coverage and fewer blind spots.
WGS may be the better fit when:
WGS can provide broader visibility across synthesis, receptor, transporter, regulatory, and astrocytic-clearance genes that may not be adequately covered by consumer arrays.
A driver map does not prescribe one universal calming protocol.
It clarifies which questions should come first.
The focus is not automatically increasing vitamin B6 or taking GABA.
The useful questions become:
The goal is identifying the bottleneck without assuming that more cofactor is always better.
The focus is reducing unnecessary amplification.
Questions include:
The issue may be sensitivity to the signal rather than excess production.
The focus is whether inhibitory signals are being received effectively.
Useful observations include:
The system may produce GABA while struggling to translate it into stable inhibition.
The focus is signal duration.
Questions include:
The issue may be how the signal is terminated and metabolized.
The focus is recovery from stimulation.
Useful observations include:
The system may tolerate individual demands but struggle when they arrive faster than glutamate can be cleared and recycled.
Genetics can identify vulnerability patterns.
It cannot determine by itself whether current symptoms are caused by anxiety, ADHD, epilepsy, medication effects, sleep deprivation, thyroid disease, migraine, substance withdrawal, trauma, infection, metabolic illness, or another condition.
A useful assessment may include:
Seek appropriate medical evaluation when neural-excitability symptoms include:
A genetic GABA and glutamate map should not be used to dismiss serious neurological or psychiatric symptoms as a supplement imbalance.
A DNA result should not be used to start, stop, or change benzodiazepines, anticonvulsants, sleep medications, gabapentinoids, alcohol use, or other GABA-active substances without appropriate medical guidance.
Abruptly stopping some GABA-active medications or heavy alcohol use can cause dangerous withdrawal, including seizures.
Medication and supplement response depends on:
The same caution applies to supplements marketed as GABA or glutamate modulators.
A genetic pathway result does not establish that a substance is safe, needed, or correctly dosed.
Mutant identifies context.
It does not prescribe neural-excitability treatment.
If you have been trying to solve overstimulation, racing thoughts, sensory sensitivity, or poor calming with generic GABA advice, high-dose cofactors, restrictive diets, or random calming products, you may be missing the most important question.
The real question is:
Which part of my neural excitation-and-inhibition system is becoming unstable?
Mutant organizes your raw DNA data into a GABA and glutamate driver map so you can distinguish between:
You do not need another report that labels GABA as simply low or glutamate as simply high.
You need a clearer model of the biology that may be shaping overstimulation, sensory tolerance, calming, and shutdown.
Yes.
Mutant consumer DNA file analysis is designed to work with consumer raw DNA files such as 23andMe.
It can provide a first-pass view of common variants involving GABA synthesis, glutamate receptors, GABA-A receptors, neurotransmitter transport, GABA degradation, and astrocytic glutamate clearance.
Coverage varies by 23andMe version, so not every relevant variant will necessarily be present.
Yes.
AncestryDNA raw data can also be used for consumer DNA file analysis.
It may provide useful coverage for several common GABA- and glutamate-related variants, although it remains more limited than whole genome sequencing.
No.
GABA regulation involves multiple genes controlling synthesis, cofactor activation, release, receptor signaling, reuptake, degradation, and recycling.
A single result cannot determine brain GABA levels, anxiety, sensory sensitivity, or medication response.
No.
Glutamate function depends on synthesis, release, receptor subtypes, transporters, astrocytes, cellular energy, ion gradients, and recycling.
One variant cannot establish that glutamate is globally high or low.
No.
DNA can identify tendencies involving GABA-related pathways.
It cannot directly measure current GABA signaling within specific brain circuits.
Current function is also influenced by sleep, stress, medications, nutrition, illness, hormones, alcohol, and environment.
No.
A genetic analysis may identify patterns involving receptor sensitivity or clearance reserve.
It cannot directly determine current glutamate concentrations in the brain.
Glutamate is the brain’s principal excitatory neurotransmitter, while GABA is its principal inhibitory neurotransmitter.
That description is useful but simplified. Their effects depend on receptor type, brain region, timing, concentration, development, and network context.
Not by itself.
GAD1 encodes GAD67, one of the enzymes that converts glutamate into GABA.
A common variant may modestly influence regulation, but it does not establish a clinically meaningful GABA deficiency.
Mutant looks for convergence across GAD1, GAD2, cofactor support, symptoms, and downstream pathways.
GAD1 encodes GAD67 and GAD2 encodes GAD65.
Both synthesize GABA, but they differ in cellular localization, regulation, and their relative contributions to baseline versus activity-linked GABA production.
Active vitamin B6 is required by glutamate decarboxylase enzymes.
However, taking more vitamin B6 does not guarantee increased or improved GABA signaling.
The pathway may not be B6-limited, and excessive supplemental B6 can cause harm.
Possible explanations include:
A reaction does not directly reveal whether GABA is high or low.
Not by itself.
GRIN2B encodes an NMDA-receptor subunit.
Different variants can have different functional effects, and common regulatory SNPs should not be equated with rare pathogenic variants.
A result becomes meaningful only in context.
The NMDA receptor is one type of glutamate receptor.
It contributes to synaptic plasticity, learning, memory, development, and calcium-dependent signaling.
Both insufficient and excessive NMDA activity can be problematic.
Magnesium participates in the voltage-dependent regulation of NMDA-receptor channels.
That does not mean every neural-excitability problem is caused by magnesium deficiency or that supplemental magnesium will correct a GRIN2B-related pattern.
No.
These genes encode GABA-A receptor subunits and may contribute to individual differences in inhibitory signaling.
Research associations with anxiety-related traits have been inconsistent, and one variant cannot diagnose anxiety or predict treatment response.
Possible explanations include:
The response should be interpreted as context, not as a direct neurotransmitter test.
The extent to which supplemental GABA directly reaches the human brain remains uncertain and may vary by product, dose, physiology, and indirect gut or peripheral effects.
A response to oral GABA does not prove that it entered the brain or corrected a brain GABA deficiency.
SLC6A1 encodes GAT1, one of the main GABA transporters in the brain.
It helps regulate extracellular GABA by transporting it into neurons and glial cells.
ABAT helps convert GABA into succinic semialdehyde.
ALDH5A1 then participates in processing that intermediate within the mitochondrial GABA-shunt pathway.
Usually not.
Rare pathogenic variants can cause serious disorders, but common SNPs are not equivalent.
Potentially pathogenic findings require clinical confirmation and appropriate genetics evaluation.
SLC1A2 encodes EAAT2 and SLC1A3 encodes EAAT1.
These transporters are strongly associated with astrocytic clearance of extracellular glutamate.
Astrocytes are support cells in the nervous system.
Among other functions, they help regulate extracellular ions, provide metabolic support, clear neurotransmitters, and recycle glutamate through the glutamate-glutamine cycle.
Fatigue and neural activation are not opposites.
A person may have low physical or cognitive energy while stress, glutamate receptors, catecholamines, histamine, or poor inhibitory control keep the nervous system activated.
This can produce the familiar tired-but-wired state.
Sleep loss can reduce emotional regulation, increase stress activation, alter neurotransmitter signaling, and lower the threshold for sensory overload.
A Circadian hub pattern may therefore amplify an underlying GABA/glutamate vulnerability.
Stress can increase neural demand and reduce the amount of inhibitory reserve available to contain activation.
The experience may involve both stress-axis mobilization and glutamate-related excitability rather than one isolated neurotransmitter change.
Dietary glutamate does not directly determine synaptic glutamate levels because the brain regulates its internal environment.
Food reactions may still occur for other reasons, so the timing and full symptom pattern matter.
Routine peripheral neurotransmitter testing does not directly measure synaptic GABA or glutamate signaling inside specific brain circuits.
Blood or urine values should not be interpreted as direct brain neurotransmitter levels.
No.
Mutant identifies genetic vulnerability patterns involving neural excitation and inhibition.
Diagnosis requires an appropriate clinical assessment considering symptoms, history, impairment, medications, neurological findings, and alternative explanations.
Whole genome sequencing generally provides broader coverage and fewer blind spots than consumer microarrays.
It may be especially useful when:
Yes.
Mutant currently provides the initial genetic driver analysis for free as part of the platform’s early development.
The future paid product is intended to provide ongoing contextual interpretation across genetics, symptoms, labs, diet, sleep, medication, and intervention history.
Important Note: Mutant provides educational, informational genetic pattern analysis. It does not diagnose, treat, cure, or prevent disease and is not a substitute for medical advice, diagnosis, or treatment. If you are experiencing a seizure, loss of awareness, severe confusion, suicidal thoughts, or a mental health crisis, seek immediate medical help.